Exelixis to present phase 3 CELESTIAL trial results of cabozantinib at ASCO-GI Symposium
Exelixis has announced that the phase 3 CELESTIAL trial results have been accepted as a late-breaking presentation at the 2018 ASCO-GI Symposium, which is...
BiondVax, NIH sign CTA for phase 2 trial in US with universal flu vaccine
BiondVax Pharmaceuticals Ltd. has announced the signing of the clinical trial agreement (CTA) for a phase 2 clinical trial with the National Institute of...
RiboBio And GE Healthcare Enter Into A Strategic Partnership For Oligonucleotide Drug Development
At the 5th Canton Nucleic Acids Forum (CNAF) in Guangzhou, China, Guangzhou RiboBio Co., Ltd. ("RiboBio") and GE Healthcare Life Sciences ("GE") held a...
Arvinas And Macroceutics Establish DEL Screening Collaboration On Undruggable Targets
Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, and Macroceutics, Inc., today announced the establishment of...
Roche’s phase III IMpower150 study meets co-primary endpoint of progression-free survival
Roche has announced that the phase III IMpower150 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of Tecentriq...
Chugai Pharma’s phase III HAVEN 3 study evaluating emicizumab meets primary endpoint
Chugai Pharmaceutical has announced that the primary endpoint has been met for the global phase III HAVEN 3 (NCT02847637) study evaluating emicizumab (ACE910) subcutaneous...
Adocia announces positive results from phase 1 study of BioChaperone Glucagon
Adocia a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, announced top-line results of a phase 1 study...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...